Ocular Therapeutix, Inc. (OCUL) Q2 2024 Earnings Call

Investor webinar replay

Replay transcript excerpt

Please stand by, your program is about to begin. If you need assistance on today's program, please press star zero. Good morning and welcome to the Ocular Therapeutics second quarter 2024 earnings conference call. At this time, all participants are in a listen-only mode. After the prepared remarks, we will conduct a question and answer session. To ask a question, please press star one. As a reminder, this conference call is being recorded. will be available for replay on the investor relations section of the ocular therapeutics website i would now like to turn the call over to ocular's vice president of investor relations bill slattery please go ahead mr slattery good morning everyone and thank you for joining us today earlier this morning we issued a press release outlining our financial results for the second quarter 2024. make the best use of your time today Oculus Executive Chairman, President, and CEO, Dr. Praveen Dougal, will briefly provide a summary of recent business highlights so we can quickly get to your questions. Joining Dr. Dougal for the Q&A portion of the call will be Donald Notman, Chief Financial Officer, Dr. Nadia Waheed, Chief Medical Officer, Dr. Sanjay Nayak, Chief Strategy Officer, and Steve Myers, Chief Commercial Officer. We refer everyone to this morning's press release in our Form 10-Q for a comprehensive update of second quarter financial and business results. During today's call, we will be making certain forward-looking statements, and our actual results may differ materially. Please see the risk factors section of our annual report on Form 10-K and our other SEC filings for details on the risks and uncertainties relating to our business. With that, I'd like to hand the call over to Dr. Praveen Dugal to review our recent updates. Pravee...